RNS Number : 2998D
N4 Pharma PLC
09 September 2024

9 September 2024

N4 Pharma plc
("N4 Pharma" or the "Company")

Director Appointment

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce the appointment of Dr Michael Palfreyman as an independent Non-Executive Director of the Company with immediate effect.

Dr Palfreyman has more than four decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK) and has co-founded and developed several biotechnology companies including, among others, Co-Founder of Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for US$230 million and Co-Founder and CSO of Amorsa Therapeutics, Inc. developing novel treatments for depression and pain where he oversaw a successful US$180 million exit.

Dr Palfreyman currently advises Cybin Inc. listed on the New York Exchange (NYSE: CYBN) and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc. Dr Palfreyman has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals.

Dr Palfreymanis an Emeritus Fellow of the American College of Neuropsychopharmacology. He is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters.

Dr Palfreyman joins the Company's remuneration and audit committees.

Nigel Theobald, Chief Executive Officer of the Company, commented:"We are delighted to welcome someone of Mike's calibre to the board of N4 Pharma. His successful career in drug discovery and development is sure to be a great asset to the Company, as will his industry connections and contacts across the US which we are confident will help in our drive to commercialise Nuvec.®"

Mike Palfreyman, commented: "As a scientist and entrepreneur who works at the cutting edge of therapeutic development, N4 Pharma's unique delivery technologies clearly show the potential to advance the clinical applications of several promising therapeutics, and I am excited by the opportunity to join the board of this exceptional company."

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Dr Michael Gavin Palfreyman, aged 78 :

Current Directorships/Partnerships	**Past Directorships/Partnerships (within 5 years)**
Palfreyman BioPharm Advisors, LLC AlNivo Therapeutics, Inc.	Adelia Therapeutics, Inc.

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via N4 Pharma Investor Hub

Engage with us directly at N4 Pharma Investor Hub	Sign up at investors.n4pharma.com
To find out more, visit	https://investors.n4pharma.com/link/lejRpe
SP Angel CorporateFinance LLP *Nominated Adviser and Joint Broker* Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: +44(0)20 3470 0470
Turner Pope Investments (TPI) Limited *Joint Broker* Andy Thacker James Pope	Tel: +44(0)20 3657 0050

About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.

N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFESASIRIIS